Twist Bioscience Announces Appointment of Martin Kunz as Senior Vice President, Operations

Announces Executive Promotions of Mark Daniels, Patrick Finn,
Ph.D., and Patrick Weiss

SAN FRANCISCO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/DNA?src=hash” target=”_blank”gt;#DNAlt;/agt;–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic DNA
manufactured on its silicon platform, today announced the appointment of
Martin Kunz as senior vice president of operations. His responsibilities
will include overseeing global operations together with software
development and information technology.

“Martin brings exceptional operational and market expertise specific to
DNA synthesis and will be an incredible resource to lead these teams,”
said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. “We look
forward to his invaluable insights and guidance as we continue to grow
and mature as a productive organization.”

Mr. Kunz brings more than 20 years of experience in business operations
and DNA synthesis expertise to Twist. Most recently, he served as
president of Eurofins Genomics US, where he implemented a new synthesis
platform and was responsible for increasing production volume for both
the synthesis and sequencing businesses. Prior to serving as president,
he served as chief technology officer where his focus was building IT
off-shore capacity and designing a new IT systems landscape for genomics
services. Preceding his time at Eurofins, he served as chief information
officer of Operon Biotechnologies, Inc. where he built a global
information technology team and developed and deployed a CRM, as well as
an e-commerce and a business intelligence system. Prior to joining the
biotech industry, he held a variety of positions at various companies
throughout Switzerland, including sales, QA and business analyst. Mr.
Kunz received his B.S. in Engineering from the H.F. Technology and
Management School (TGZ) in Zurich, Switzerland.

“I’m enthusiastic about joining Twist at this exciting time in its
growth trajectory and look forward to bringing a new perspective as we
accelerate our global expansion,” commented Mr. Kunz.

Promotion of Key Executives

In addition to the appointment of Martin Kunz as senior vice president
of operations, Twist announced the promotion of Mark Daniels to senior
vice president, chief legal officer, chief ethics and compliance officer
and secretary and Patrick (Paddy) Finn, Ph.D., to senior vice president,
commercial operations. Patrick Weiss, who previously served as senior
vice president of operations, will now focus on innovation as senior
vice president, research and development and general manager of data
storage.

“Paddy’s leadership has been instrumental in growing our commercial
organization and revenue stream significantly, expanding from $2.3
million in fiscal 2016 to $25.4 million in fiscal 2018,” Dr. Leproust
remarked. “Patrick led the expansion of our operations infrastructure as
we scaled from our alpha launch through to commercial stage for multiple
products, playing an integral role in ensuring Twist delivers the
highest quality DNA on the market, and will now take that same
excellence and apply it to developing products including data storage.
Mark has been instrumental in guiding processes and procedures through a
complex legal framework, guiding the company from private to public.
These seasoned veterans have made vital contributions to the
organization, and bring structure, stability and leadership to our
dynamically growing company.”

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology
company that has developed a disruptive DNA synthesis platform to
industrialize the engineering of biology. The core of the platform is a
proprietary technology that pioneers a new method of manufacturing
synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging
its unique technology to manufacture a broad range of synthetic
DNA-based products, including synthetic genes, tools for next-generation
sequencing (NGS) preparation, and antibody libraries for drug discovery
and development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist makes
products for use across many industries including healthcare, industrial
chemicals, agriculture and academic research.

Follow us on Twitter
| Facebook
| LinkedIn
| YouTube

This press release contains forward-looking statements. All
statements other than statements of historical facts contained herein
are forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including, but
not limited to, Twist Bioscience’s belief regarding the future growth
and expansion of the company. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors that
may cause Twist Bioscience’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and uncertainties
of rapidly changing technologies and extensive competition in synthetic
biology could make the products Twist Bioscience is developing obsolete
or non-competitive; uncertainties of the retention of a significant
customer; risks of third party claims alleging infringement of patents
and proprietary rights or seeking to invalidate Twist Bioscience’s
patents or proprietary rights; and the risk that Twist Bioscience’s
proprietary rights may be insufficient to protect its technologies. For
a further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these forward-looking
statements, as well as risks relating to Twist Bioscience’s business in
general, see Twist Bioscience’s risk factors set forth in Twist
Bioscience’s Annual Report on Form 10-K for the year ended September 30,
2018 filed with the Securities and Exchange Commission on December 20,
2018. Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise.

Contacts

Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com

error: Content is protected !!